In March 2019 Secura Bio acquired the global rights of Farydak from Novartis, and announced that Inceptua is appointed as distributor for Farydak in the Nordic region.
Farydak is an anti-cancer medicine that contains the active substance panobinostat, which belongs to a group of medicines called pan-deacetylase inhibitors.
Farydak is used to treat adult patients with a rare type of blood cancer called multiple myeloma. Multiple myeloma is a disorder of plasma cells (a type of blood cell) that grow out of control in the bone marrow.
Farydak blocks the growth of cancerous plasma cells and reduces the number of cancer cells. Farydak is always used together with two other medicines: bortezomib and dexamethasone.
The medicine can only be obtained with a prescription.
Farydak Patient Information Leaflet.
The European Medicines Agency (EMA) is an agency of the European Union (EU). The Agency is responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies for use in the EU. See EMA guidance on Farydak:
Medicines in Northern Ireland fall under the remit of the European Medicines Agency (EMA) whilst medicines in Great Britain (England, Scotland and Wales) fall under the remit of the Medicines and Healthcare products Regulatory Agency (MHRA) following the UK leaving the European Union. These agencies are responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies.
If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for Farydak please follow these links:
Safety and adverse events
Patient safety is a key priority for us. For any suspected adverse drug reactions or quality complains associated with Farydak supplied by Inceptua, please contact:
24/7 reporting of adverse events: +43 (0)650 711 50 97